Data at the 2026 American Academy of Dermatology meeting pointed to intensified competition in atopic dermatitis as targeted oral therapies move closer to challenging injected biologics. The roundup described multiple companies presenting late-breaking results, including a highlighted oral approach from Connect Biopharma. At the same meeting, Connect Biopharma reported 52-week improvements across multiple endpoints in its phase 3 eczema trial, framing the data as evidence its oral medicine could outperform Dupixent. For biotech decision-makers, the central takeaway is mechanism-based switching: oral selectivity is increasingly being positioned as a convenience and access lever, while investors may reassess the pricing and uptake assumptions traditionally associated with injection-dominant eczema care.